Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | LPL | P06858 | 2/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LPO | P22079 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9451409 | 0.79 | HDAC4 (0.47) | HDAC4KDM5BBRD4PDK1CCNC | |
| SCHEMBL10194263 | 0.79 | KDM4E (0.51) | HDAC4KDM5BBRD4PDK1CCNC | |
| SCHEMBL3462133 | 0.76 | HDAC4 (0.46) | HDAC4KDM5BBRD4CCNCCDK8 | |
| SCHEMBL9281044 | 0.76 | HDAC4 (0.54) | HDAC4BRD4PDK1CCNCCDK8 | |
| SCHEMBL16628325 | 0.76 | HDAC4 (0.43) | HDAC4KDM5BBRD4PDK1CCNC | |
| SCHEMBL2326291 | 0.76 | IDO1 (0.47) | HDAC4KDM5BBRD4CCNCCDK8 | |
| SCHEMBL10558737 | 0.76 | NR1H2 (0.45) | HDAC4KDM5BBRD4KDM4ENPC1 | |
| SCHEMBL77337 | 0.76 | HDAC4 (0.47) | HDAC4KDM5BBRD4CCNCCDK8 | |
| SCHEMBL21776938 | 0.75 | HDAC4 (0.50) | HDAC4KDM5BBRD4PDK1EDNRA | |
| SCHEMBL27031386 | 0.75 | HDAC4 (0.44) | HDAC4KDM5BBRD4PDK1CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133961-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS FOR THE TREATMENT OF CHRONIC DISEASES | PFIZER INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4313967-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | UNIVERSITY OF DELAWARE (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| US-20220106278-A1 | REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS | UNIVERSITY OF DELAWARE (US) | 2022-04-07 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767302-B2 | Reagents and methods for tetrazine synthesis | TST, CYP4F8, CYP4Z1 | HDAC4 1822/4885CA2 2171/4885LPL 3408/4885 |
| US-20220106278-A1 | REAGENTS AND METHODS FOR TETRAZINE SYNTHESIS | TST, CYP4F8, CYP4Z1 | HDAC4 1822/4885CA2 2171/4885LPL 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.